NRC — Human Health Therapeutics Research Centre
Canada
Collaborate on human health therapeutics R&D
grant_single_labels|summary
grant_single|eligibleFinancing
- grant_single|noCondition
grant_single|deadlines
- grant_single|openingDateNovember 14, 2019
grant_single|financingType
Expert Advice
Researchers And Facilities
grant_single|eligibleIndustries
- Manufacturing
- Professional, scientific and technical services
- Health care and social assistance
grant_single|grantors
- National Research Council Canada (NRC)
- Government of Canada
grant_single|status
grant_card_status|open
grant_single_labels|preview
Access technical and advisory services, research facilities and licensing opportunities for human health therapeutics research.
grant_single_labels|projects
grant_single|admissibleProjectsExample
$ 750,000
Creation of an innovative biologic to tackle autoimmune diseases
$ 900,000
Research and development of novel biologics for cancer treatment
$ 600,000
Development of a new gene therapy targeting rare genetic disorders
$ 750,000
Production of a novel biologic for infectious disease treatment
$ 850,000
Development of cell therapy for treating cardiovascular diseases
$ 400,000
Optimization of biomanufacturing processes for complex biologics
grant_single_labels|admissibility
grant_eligibility_criteria|eligible_expenses
This grant supports initiatives aimed at advancing biologics development and production, with a focus on tackling complex health challenges. Eligible projects include collaboration across research and development, innovative production processes, and therapy advancements.
- Design and development of innovative biologics for emerging infections, cancer, and neurological diseases.
- Biomanufacturing improvements to optimize production processes for complex biologics.
- Advancement of cell and gene therapies through collaborative projects.
- Preclinical research and development utilizing in vivo and in vitro testing.
- Scaling up bioprocesses for clinical trial material production compliant with GMP.
- Collaborative research initiatives to combat antimicrobial resistance.
- Development of CAR T-cell cancer therapies made in Canada.
grant_single_labels|criteria
There are evaluation and selection criteria for this grant. The evaluation and selection criteria are as follows:
- Relevance of the project to advancing novel biologics
- Scientific merit and innovation of the proposed research
- Feasibility and technical soundness of the project
- Alignment with the organization's strategic priorities
- Potential impact on public health and patient outcomes
grant_single_labels|register
Here are the steps to submit an application for this grant:
- Step 1: Preliminary Research and Collaboration
- Review the research publications and programs to identify areas of expertise that align with your project.
- Contact Sue Twine or Paul Payette to discuss potential collaboration opportunities and gain insights about the grant application process.
- Step 2: Draft Proposal
- Prepare a proposal that outlines the project's objectives, research methodologies, and anticipated outcomes.
- Include details about how your project will contribute to the advancement of biologics, biomanufacturing, or cell and gene therapies.
- Step 3: Compile Supporting Documents
- Gather all necessary documents including project timelines, budgets, letters of support from collaborators, and CVs of key team members.
- Ensure all documents adhere to the grant's guidelines and requirements.
- Step 4: Submit Application
- Email the completed application and supporting documents to the appropriate contact as specified, such as Susan.Twine@nrc-cnrc.gc.ca or Paul.Payette@nrc-cnrc.gc.ca.
- Make sure to submit the application before any specified deadline to ensure consideration.
- Step 5: Confirmation and Follow-Up
- Await confirmation of receipt from the grant body.
- Follow up if needed, using the contact information provided, to ensure the application is being processed.
grant_single_labels|otherInfo
Here are additional relevant details for this grant:
- Collaboration with industry, hospitals, health networks, academia, and government is encouraged to advance novel biologics.
- Access to multidisciplinary expertise and leading-edge facilities is available for the biologics development process, from discovery to clinical material production.
- Support for generating high-potential candidates using advanced proprietary technologies is provided.
- Preclinical R&D capabilities include small-scale manufacturing and both in vivo and in vitro testing expertise.
- Bioprocess improvements can be conducted in specialized R&D labs focusing on analytics, modelling, and intensification.
- Production facilities are available for optimizing bioprocesses and producing clinical trial materials compliant with good manufacturing practices (GMP).
- A directory of science professionals and researcher profiles is accessible, offering insights into their projects and expertise.
